Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser.
Publication/Presentation Date
8-1-2014
Abstract
An infant of 36 weeks' postmenstrual age (PMA) and 25 weeks' gestation received bilateral intravitreal bevacizumab injections for type 1 retinopathy of prematurity. He underwent laser photocoagulation in both eyes 5 days later, confluent except for 1 clock hour obscured by hemorrhage in the left eye. Despite initial regression, neovascularization in both vascularized and lasered retina with plus disease recurred, requiring repeat laser bilaterally at 51 weeks' PMA and vitrectomy in the left eye at 54 weeks' PMA. Whereas late recurrence is thought to occur rarely after laser treatment, infants who have received both bevacizumab injections and laser may still require long-term surveillance for recurrence. In this case, fundus photography proved valuable for appreciating recurrent plus disease because the initial treatments had resulted in marked retinal vessel attenuation.
Volume
18
Issue
4
First Page
402
Last Page
404
ISSN
1528-3933
Published In/Presented At
Chen, W., Binenbaum, G., Karp, K., Baumritter, A., Pearson, D. J., Maguire, A. M., & Quinn, G. E. (2014). Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 18(4), 402–404. https://doi.org/10.1016/j.jaapos.2014.03.011
Disciplines
Medicine and Health Sciences | Pediatrics
PubMedID
25087645
Department(s)
Department of Pediatrics
Document Type
Article